Gränslös Innovation

1. Gränslös Innovation Cristina Glad Skånska Utvecklingsdagen 14 november 2005 Presentationen har inför publicering på skane.se rensats på bildelement pga utrymmesskäl.

2. 14 samverkande Universitet26 sjukhus varav 11 universitetssjukhus

3. Acumulated total of new biotech companies (excluding medical technology and CROs) Total no of start-ups: 110 Still existing 2005: 95 Companies closed: 10 Mergers/Acquisitions: 5

4. Medicon Valley Blockbusters Cipramil (antidepressive) Lundbeck Turbuhaler (powder inhalator) AstraZeneca, Lund NovoPen (insulin) Novo Nordisk

5. Swedish regions and Copenhagen - companies with an international market, excl. sales Wide-range research & development K108-LU5600 K96-LU470 K91-LU97 without - with - without - with product Narrow research & development K92-LU50 Product development K140-MT380 K132-MT278 Consultancy Production K81-LP55 K72-LP320 K76-LP/LU380 Umeå Uppsala - Stockholm - Str-näs Linköping Gothenburg Others Malmö/Lund Copenhagen Medicon Valley K10-BP1231 Red=pharma; Pink= CRO; Yellow=medtech; Blue=biotech foods Violet=pharma production (only); Brown=biotech/bioproduction

6. The European biotech landscape Source: Critical I Limited

7. Bioteknikbolagen I Europa är många men har svårt att växa ”At the point at which Europe’s companies ought to be taking off, most of them appear to run out of financial runway” Source: Critical I Limited

9. Getting venture investment in European biotechnology depends on being in the right place Source: Critical I Limited

10. Capital to Biotech(Nov 2004-July 2005) BioEtt (Nov-04) 0.6 Celltrix (Nov-04) 1 Symphogen (Nov-04) 21 Probi (IPO) (Dec-04)4 CMC (Jan-05) 14 Ultrazonix (Jan-05) 3 Zealand Pharma (Feb-05)26 LiPlasome (Mar-05) 6 SpectraCure (Mar-05) 2 TopoTarget (Mar-05) 15 Evolva (Mar-05) 14 Mitra Medical (Mar-05) 3 Acadia (Apr-05) 30 NsGene (May-05) 4 LifeCyclePharma (May-05)15 Exiqon (May-05) 17 Pharmexa (publ.) (Jun-05) 40 ProstaLund (Jun-05) 3 TopoTarget (IPO)(Jul-05)31 Medtentia (Jul-05) 1 Active Biotech (Jul-05) 18 TOTAL 60>200 M€

11. Medicon Valley Academy Initiative 1995 from universities and big pharma companies 2000:Private membership based non profit organisation Universities, hospitals & companies (260 members) 2 nations – 2 systems

12. Innovation Potential in Medicon Valley 300 million € university research 3200 publications/yr >150 inventions/yr Research Technology Transfer 400 bio-companies 40,000 employees Companies From BioScience to New Jobs in Medicon Valley - A Medicon Valley Academy Strategic Report

13. Innovation Report 2004Recommendationsto improve the competitiveness of Medicon Valley • More commercial know-how into Technology Transfer Organisations • 2) Regional TTO cooperation (!) • 3) Funding for Proof-of-Concept studies • 4) Seed investments across Øresund (!) • 5) Tax incentives for the Young Biotech Industry From BioScience to New Jobs in Medicon Valley - A Medicon Valley Academy Strategic Report

14. Våra Svagheter • Svårt att växa • Brist på kapital • Kompetens inom utveckling och kommersialisering • Svårt attrahera utländsk arbetskraft • Skatter och avgifter • Hjälpande infrastruktur

15. Vi måste vara attraktiva

16. Våra Styrkor • Tillgång på högutbildad personal • Tillgång på kompetens från andra företag • Samarbete med akademin • Innovationsklimatet inom akademin • Lärarundantaget • Holdingbolag, Innovationsbron etc.

17. Research infrastructure investments • SWEGENE(Lund) • Postgenomic RT Programme • inSouth Western Sweden • BMC(Lund) • Bio Medical Center • CRC(Malmö) • Clinical Research Center • BRIC(Copenhagen) • Biotech Research and Innovation Center Total investments 0.3-0.4 billion €

18. ESS? LUND North Campus Area Gambro Sony Ericsson Active Biotech Chemical Centre Ideon Science Park Cryo-EM Microarray Genomic Ecology University Hospital LTH Proteomics Astra Zeneca Transgenic core facility BMC School of Economics Bioinformatics MAX-lab 500 m